Sabrina Serani

New data highlightstaletrectinib's impressive efficacy and safety in treating ROS1-positive non–small cell lung cancer, offering hope for patients.

Interim results from the CAReS trial highlight ART27.13's potential to combat cancer-related weight loss, offering hope for effective treatment in CACS.

Pirtobrutinib shows significant promise in improving progression-free survival for patients with treatment-naive CLL/SLL, challenging traditional therapies.

A groundbreaking clinical trial explores botensilimab/balstilimab combination therapy, offering new hope for advanced colorectal cancer patients lacking effective immunotherapy options.

Researchers identify IL-6 as a key biomarker predicting resistance to CDK4/6 inhibitors in metastatic breast cancer, highlighting new therapeutic targets.

Rezolute streamlines the clinical pathway for ersodetug, expediting treatment for tumor hyperinsulinism and addressing urgent patient needs.

FDA fast-tracks CER-1236, a novel immunotherapy for acute myeloid leukemia, enhancing its development and potential market entry.

A groundbreaking study shows trastuzumab pamirtecan significantly improves progression-free survival in HER2-positive breast cancer patients, marking a major oncology advancement.

Lantern Pharma advances pediatric CNS cancer treatment with FDA guidance on LP-184 trial, targeting rare tumors and enhancing therapy with spironolactone.

Guardant Health's Shield test shows promising results in colorectal cancer screening, enhancing early detection and patient access with a noninvasive blood test.

Epcoritamab shows promise for outpatient treatment of relapsed DLBCL, enhancing patient access and quality of life while managing side effects effectively.

New research unveils a promising monoclonal antibody therapy targeting CALR mutations in essential thrombocythemia, aiming to improve patient outcomes.

The FDA approves Bildyos and Bilprevda, expanding treatment options for osteoporosis and cancer-related bone loss, enhancing patient access and affordability.

Zongertinib receives FDA breakthrough therapy designation for treating HER2-mutant non-small cell lung cancer, promising new hope for patients.

Researchers explore DNA methylation patterns for early ovarian cancer detection, aiming to improve survival rates through innovative blood tests.

Research advances in blood cancer treatment enhance donor matching and reduce graft-vs-host disease, improving access to life-saving transplants for diverse patients.

A new triple therapy shows promising results for treating BRAF V600E-mutant metastatic colorectal cancer, significantly improving patient outcomes.

Zymeworks discontinues ZW171 clinical development after phase 1 trial reveals unfavorable benefit-risk profile, shifting focus to other promising candidates.

Researchers explore TAF1's role in leukemia, revealing potential targeted therapies that could transform treatment approaches for acute myeloid leukemia.

New clinical trial results reveal annamycin's promise in treating relapsed AML, showing improved survival rates and a favorable safety profile.

The FDA approves a long-acting injectable for advanced prostate cancer, offering a convenient quarterly dosing option and improved patient care.

Sonrotoclax shows promise as a new treatment for relapsed/refractory mantle cell lymphoma, achieving significant response rates in heavily pretreated patients.

Abemaciclib significantly enhances survival rates in high-risk early breast cancer, establishing its role as a standard treatment alongside endocrine therapy.

A groundbreaking study reveals how the Decipher Prostate Genomic Classifier personalizes chemotherapy decisions for metastatic prostate cancer patients, enhancing treatment outcomes.

VGT-1849B receives FDA orphan drug designation, promising a targeted treatment for polycythemia vera with improved safety and efficacy.

TT125-802, a promising bromodomain inhibitor, gains FDA fast track status for treating advanced non-small cell lung cancer, addressing critical patient needs.

FDA reviews gedatolisib for advanced breast cancer, showing significant progression-free survival improvements in pivotal VIKTORIA-1 trial.

The European Commission approves tislelizumab for neoadjuvant treatment of resectable NSCLC, enhancing survival rates and offering new hope for patients.

A pivotal trial evaluates patritumab deruxtecan for advanced HR-positive, HER2-negative breast cancer, offering hope for patients after standard therapies.

A novel assay identifies low-risk patients with high-risk ER+/HER2– early breast cancer, potentially sparing them from unnecessary treatment escalation.